Moneycontrol
HomeNewsBusinessReal EstateWeWork India gets $100-million funding boost from parent company
Trending Topics

WeWork India gets $100-million funding boost from parent company

It will use the funds for prioritising growth in the Indian market over the next 36 months, the company has said.

June 05, 2020 / 18:54 IST
Story continues below Advertisement

WeWork India, the platform that provides collaborative workplace solutions, will receive $100 million in funding from WeWork Global to help boost growth, the company said in a statement.

In line with its belief that the future of work will be centred around flexible workspaces, a shift accelerated by the pandemic, WeWork India is looking to navigate this transformation by prioritising focused growth in the Indian market over the next 36 months, it said.

Story continues below Advertisement

“The fresh round of capital from our long-term partners at WeWork Global represents a vote of confidence in our strategy and will help us serve our community better,” said Karan Virwani, CEO, WeWork India.

The company sees a new opportunity in the flexible workspace industry in India and around the world.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show